206 related articles for article (PubMed ID: 6773632)
1. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.
Reitsma PH; Bijvoet OL; Verlinden-Ooms H; van der Wee-Pals LJ
Calcif Tissue Int; 1980; 32(2):145-57. PubMed ID: 6773632
[TBL] [Abstract][Full Text] [Related]
2. Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Reitsma PH; Bijvoet OL; Potokar M; van der Wee-Pals LJ; van Wijk-van Lennep MM
Calcif Tissue Int; 1983 May; 35(3):357-61. PubMed ID: 6871766
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse.
Marie PJ; Hott M; Garba MT
Bone; 1985; 6(3):193-200. PubMed ID: 4027097
[TBL] [Abstract][Full Text] [Related]
4. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
[TBL] [Abstract][Full Text] [Related]
5. Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse.
Marie PJ; Hott M; Garba MT
Calcif Tissue Int; 1985 May; 37(3):268-75. PubMed ID: 3926276
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of disodium (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate.
Reitsma PH; Bijvoet OL; Frijlink WB; Vismans FJ; van Breukelen FJ
Adv Exp Med Biol; 1980; 128():219-27. PubMed ID: 7424675
[No Abstract] [Full Text] [Related]
7. Structure-activity relationships of various bisphosphonates.
Shinoda H; Adamek G; Felix R; Fleisch H; Schenk R; Hagan P
Calcif Tissue Int; 1983; 35(1):87-99. PubMed ID: 6839194
[TBL] [Abstract][Full Text] [Related]
8. Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months.
Netelenbos JC; van Ginkel FC; Lips P; Leeuwenkamp OR; Barto R; van der Vijgh WJ; van der Wiel H; Hackeng WH
J Clin Endocrinol Metab; 1991 Jan; 72(1):223-8. PubMed ID: 1986022
[TBL] [Abstract][Full Text] [Related]
9. The effects of hydrocortisone, parathyroid hormone and the bisphosphonate, APD, on bone resorption in neonatal mouse calvaria.
Reid IR; Katz JM; Ibbertson HK; Gray DH
Calcif Tissue Int; 1986 Jan; 38(1):38-43. PubMed ID: 3079651
[TBL] [Abstract][Full Text] [Related]
10. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
[TBL] [Abstract][Full Text] [Related]
11. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.
Valkema R; Vismans FJ; Papapoulos SE; Pauwels EK; Bijvoet OL
Bone Miner; 1989 Jan; 5(2):183-92. PubMed ID: 2920240
[TBL] [Abstract][Full Text] [Related]
12. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH.
Jara A; Lee E; Stauber D; Moatamed F; Felsenfeld AJ; Kleeman CR
Kidney Int; 1999 Apr; 55(4):1434-43. PubMed ID: 10201008
[TBL] [Abstract][Full Text] [Related]
13. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
[TBL] [Abstract][Full Text] [Related]
14. Continuous infusion of 1,25-dihydroxyvitamin D3 stimulates bone turnover in the normal young mouse.
Marie PJ; Travers R
Calcif Tissue Int; 1983 Jul; 35(4-5):418-25. PubMed ID: 6688545
[TBL] [Abstract][Full Text] [Related]
15. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats.
Ferretti JL; Cointry G; Capozza R; Montuori E; Roldán E; Pérez Lloret A
Bone Miner; 1990 Oct; 11(1):111-22. PubMed ID: 2268736
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.
Heynen G; Delwaide P; Bijvoet OL; Franchimont P
Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650
[No Abstract] [Full Text] [Related]
17. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Frijlink WB; Bijvoet OL; te Velde J; Heynen G
Lancet; 1979 Apr; 1(8120):799-803. PubMed ID: 86042
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
[TBL] [Abstract][Full Text] [Related]
19. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat.
Kapitola J; Zák J; Lacinová Z; Justová V
Physiol Res; 2000; 49 Suppl 1():S101-6. PubMed ID: 10984078
[TBL] [Abstract][Full Text] [Related]
20. A new diphosphonate: dissociation between effects on cells and mineral in rats and a preliminary trial in Paget's disease.
Lemkes HH; Reitsma PH; Frijlink W; Verlinden-Ooms H; Bijvoet OL
Adv Exp Med Biol; 1978; 103():459-69. PubMed ID: 362851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
